“Our technical team—including Deputy CEO Dr. Fung Yan-ho, Operations Director Kwok Man-yuk, and Clinical & Regulatory Manager Li Wai-man—was interviewed by Ming Pao to discuss the PURE Index Test urine test technology.
Excerpt from the article: ‘Currently, the only definitive method for diagnosing prostate cancer is a biopsy, which involves inserting a needle through the patient’s rectum to extract prostate tissue under ultrasound guidance. Since ultrasound cannot detect prostate cancer directly, doctors must randomly sample prostate tissue, typically extracting 18 to 24 samples. In higher-risk cases, MRI is first used to detect suspicious areas before proceeding with the biopsy. Patients often experience pain, urinary or rectal bleeding, and fever after the procedure. This is precisely why the medical community continues to seek alternative methods for diagnosing prostate cancer—aiming to reduce biopsies while ensuring low-risk detection.’
For the full article, please visit: 🔗 Ming Pao News
